Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

Summary

It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in treatment of Egyptian patients with chronic hepatitis C for 48 weeks. hepatitis C virus (HCV) viral load will be assessed during therapy at weeks 12, 24 and end of treatment, as well as 24 weeks after therapy is completed.

Timeline

Start

2012-08

Primary completion

2014-08

Completion

2014-08

Drugs

Indications